In the present study, the role of the C-terminal a-helical domain (amino acid (aa) 195-208) of the von HippelLindau (VHL) tumour suppressor was investigated. Deletions of the VHL C-terminus up to the naturally occurring 195-Gln-Term resulted in hypoxia-inducible factor (HIF)-1a downregulation in renal cell carcinoma (RCC)4 cells during normoxia, suggesting that this domain is not an absolute requirement for the ubiquitination of HIF-1a. However, detailed investigation of the ubiquitin protein isopeptide ligase ubiquitin ligase properties of VHL revealed C-terminal deletions to cause a significant impairment of HIF-1a ubiquitination, which is shown to be due to a loss in high-affinity binding to the target substrate. When VHL regulation of both HIF-1a N-and C-terminal oxygen-dependent degradation domains (HIF-ODDD) was investigated, it was found that only ubiquitination of the C-terminal HIF-ODDD was affected by the deletion of the VHL C-terminus. When RCC4 cells expressing C-terminal truncations of VHL were exposed to graded hypoxia, differences in the induction of HIF-1a were observed in comparison with full-length VHL, with a shift in the maximal induction of HIF-1a to a higher oxygen tension. These changes were accompanied by increased glucose transporter 1 expression, p300 CH1 domain binding and HIF-mediated reporter activity. We have thus defined a role for the Cterminal a-helical domain of VHL in the regulation of HIF-1a.
Introduction
The 213 amino acid (aa) von Hippel-Lindau protein (VHL) plays a role in tumour suppression by forming part of a larger ubiquitin protein isopeptide ligase (E3) complex that bears structural similarities with the yeast Skp1-Cdc53-F-box (SCF) complex (see, for a review, Clifford and Maher, 2000) . Likewise, the VHL/E3 ligase may share some of the functions of the SCF complex, including transcriptional control and cell division. To date, the VHL/E3 ligase has been shown to consist of at least four other proteins; elongin B/C, Cullin-2 and Rbx-1. Collectively, this complex binds and ubiquitinates the target protein in conjunction with one or more members of the E2 ligase family.
Mutations in the VHL gene can result in highly vascular tumours of the kidney, CNS, eye and pancreas that affect approximately 1 in 35 000 people (for a review, see Ohh and Kaelin, 1999) . In general, the constellation of VHL mutations found in VHL disease fall into two hotspots; those affecting interactions with the ubiquitination target (aa 80-120) and those affecting binding to the elongin-B/C heterodimer (aa 150-180). Interestingly, it is only the latter of these that are found to transmit through the germline. Both mutation types disrupt ubiquitination of the transcription factors hypoxia-inducible factor (HIF)-1a and HIF-like factors (HLF), leading to their overexpression. The deregulated expression of various genes controlled by these factors is thought to contribute to the VHL disease phenotype (Ohh and Kaelin, 1999; Clifford and Maher, 2000) . There are, however, mutations outside of conventional VHL hotspots that can result in VHL syndrome. One such area is the C-terminus of VHL, an a-helical domain that extends from aa 195-208 (Stebbins et al., 1999; Hon et al., 2002; Min et al., 2002) . Mutations in this domain, including a termination at position aa 195 (Crossey et al., 1994) , result in a high risk of phaeochromocytoma, haemangioblastoma and renal cell carcinoma (RCC), three tumour types commonly associated with VHL disease. When investigated in RCC cells, the C-terminus of VHL appears to be involved in fibronectin binding and matrix formation, since deletions up to aa 195 or 198 result in a loss of both relative to the full-length protein Clifford et al., 2001 , Hoffman et al., 2001 . By contrast, a deletion up to aa 198 does not appear to affect the downregulation of glucose transporter 1 (GLUT1) or vascular endothelial growth factor expression , genes controlled by HIF-1a/HLF.
The C-terminal a-helix of VHL has been suggested to be part of the substrate-binding b-domain of VHL, since it forms hydrophobic interactions with one of the b-sheets that forms part of the seven stranded b-sandwich extending from aa 64 to 154 (see Stebbins et al., 1999) . In line with these observations, there are reports that deletions in the C-terminus of VHL impair ubiquitin ligase activity (Lisztwan et al., 1999) . To better understand the functional role of the C-terminal a-helical domain of VHL, we systematically investigated its contribution to HIF-1a regulation by characterizing properties associated with E3 ligase substrate binding and ubiquitin conjugation. The results presented suggest a specific role for the C-terminal a-helical domain of VHL in its E3 ubiquitin ligase activity and consequent tumour suppressor function.
Experimental procedures
Cell culture, maintenance, generation of stable cell lines RCC4 cells were the gift of Professor CHCM Buys, Department of Medical Genetics, University of Groningen, Groningen, The Netherlands. The 786-0 cells were obtained from ATCC. All cell lines used in this study were maintained in Dulbecco's modified Eagle's medium/10% foetal calf serum (Invitrogen), at 5% CO 2 , 21% O 2 , 371C. Stable cell lines were generated by first transfecting the appropriate antibiotic resistance carrying plasmid cDNA (using the elongation factor promoter-internal ribosome entry site (EF-IRES)-puromycin backbone) into cells at approximately 70% confluence. Lipofectamine (Invitrogen) was used for transfection throughout these procedures according to the manufacturer's instructions, with antibiotic (puromycin, Sigma Chemicals) added 48 h post-transfection at 1 mg/ml. Colonies were selected and further grown at a puromycin concentration of 5 mg/ml. Cells expressing stably incorporated recombinant DNA were routinely passaged at 5 mg/ml throughout the duration of these studies.
Plasmids, cDNA subcloning, primers, generation of fusion proteins and fluorescence
The VHL cDNA used in these studies was generously provided as an N-terminal haemagglutin (HA) fusion construct in the pRCCV vector by Dr WG Kaelin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. To generate C-terminal truncations of VHL, the following primer pairs were used with the HA-VHL/EF-IRES-puro vector as templates: 5 0 -GGCGAATTCGTCAGCGC TCCTGTGCCAGCC-GCTCCAG-3 0 and 5 0 -GAATTA TTTGTGCCAGCTCTCAATGTTGACGGA-3 0 ; and VHL-201, 5 0 -GGCG-AATTCGTCACAGCCGCTCCA GGTCTTT-3 0 and 5 0 -GAATTATT-TGTGCCAGCTC-TCAATGTTGACGGA-3 0 . To generate VHL-197, the following primers were used: 5 0 -GCGAATTCGT-CAGTCTTTCTGCACATTTGG-3 0 , to generate a truncated VHL at position 197 with a stop codon followed by a 3 0 EcoRI site, paired with: 5 0 -GGCGCGGAGGAG GCAGGCGTC-3 0 using VHL/EF-IRES-puro as the template, and the amplified product digested with BglII/ EcoRI . was generated by substituting at position 583, a C to T base change via site-directed mutagenesis (Quick-Change Kit, Stratagene). C-terminal constructs were subcloned into parent VHL using BglII/EcoRI and verified by automated DNA sequencing.
Extract preparation, antibodies, immunoblotting and immunoprecipitation
To prepare cell extracts, cells were harvested by scraping with a rubber policeman in ice-cold PBS, then lysed with WCE buffer as described previously (Roberts and Whitelaw, 1999) . In both cases, buffers were supplemented with protease inhibitor tablets (Roche Molecular Biochemicals), one tablet per 15 ml buffer, as per the manufacturer's instructions. Cell extracts were then assayed for protein content using a kit supplied by Pierce Chemicals, following the manufacturer's guidelines. Samples were then boiled in SDS-PAGE sample buffer and subjected to electrophoresis. In general, 100-200 mg of protein sample was routinely loaded in order to detect HIF-1a. Gels were than transferred to nitrocellulose and probed with either monoclonal anti-HIF-1a IgG, (Transduction Laboratories) or anti-HA, 12CA5 IgG (Roche Molecular Biochemicals). Anti-GLUT1 IgG was obtained from Alpha Diagnostic. Anti-BiP IgG was obtained from Santa-Cruz Biotechnology. For immunoprecipitation, cells were lysed in WCE buffer and approximately 1 mg of WCE was used. The extract was mixed with 12CA5 IgG and allowed to mix for 2 h at 41C. Protein-A sepharose (AmershamPharmacia Biotech) was added to the mixture for a further 1 h and the bound material washed 3 Â 10 min at 41C with a buffer consisting of 50 mM Tris-HCl pH 8.0, 0.5% Triton X-100 and 500 mM KCl or 1.0 M KCl. SDS-PAGE sample buffer was then added to the immunoprecipitates and the extracts boiled prior to electrophoresis and immunoblotting.
Exposure of cells to hypoxia and proteasome inhibitor
In order to expose cells to hypoxia (o1% O 2 ), cells were placed in 2 l air-tight containers containing a single anaerobic sachet (Oxoid). Graded hypoxia was achieved by equilibrating purpose-built air-tight containers with premixed gases containing either 5% O 2 , 5% CO 2 , balance nitrogen, or 2% O 2 , 5% CO 2 , balance nitrogen (BOC gases, Australia). Unless otherwise specified in the text, hypoxia refers to o1% O 2 . In the case where cells were treated with MG132 (Biomol), the chemical was first dissolved in stock dimethyl sulphoxide (DMSO) and then diluted to a DMSO/70% ethanol solution prior to addition to the cells.
Generation of HIF-ODDD, stable expression in HeLa cells and purification using nickel resin chromatography
The cDNA encoding the HIF-1a oxygen-dependent degradation domain (HIF-ODDD), N-terminal aa 343-509 or C-terminal, aa 416-580, was amplified from a full-length HIF-1a template using the following primer pairs: 5 0 -GCAGATCTAGTGGTATTATTCAGCA-C GAC-3 0 and 5 0 -GCTCTAGATCAACTTTGTCTAGT GCTTCC-3 0 ; 5 0 -GAAGATC-TGGCAGCAACGACA CAGAAAC-3 0 and 5 0 -GCTCTAGATCACAACTGAT CGAA-GGAACGTAA-3 0 . The amplified product was cut with BgLII/XbaI and ligated into an N-terminal 6 Â His/6 Â Myc-tagged cDNA encoding human HIF-1a cut with BgLII/SpeI, to generate 6 Â His/6 Â Myctagged ODDD with the first 28 aa of HIF-1a preceding the fused ODDD. Previous experiments (Roberts et al., unpublished observations) revealed these domains to be necessary and sufficient for oxygen-dependent degradation mediated by proline 402 (N-terminal) and proline 564 (C-terminal). These constructs, expressed in EF/ IRES/neo, were stably transfected into 786-0/VHL or 786-0/VHL-194 cells and selected for using G418. Cells expressing N-or C-terminal HIF-ODDD were harvested from confluent 75 cm 2 flasks following treatment with dipyridyl (DPP) or MG132 and lysed in 1 ml of an ice-cold buffer containing 100 mM KPO4 buffer pH 7.5, 20 mM imidazole, 450 mM KCl, 0.05% Triton X-100 and EDTA-free complete protease inhibitor (Roche Molecular Biochemicals). Lysate was centrifuged at 10 000 g for 10 min and the supernatant incubated at 41C with 400 ml bed volume of nickel resin (Qiagen) for 3 h. Samples were washed 3 Â with lysis buffer and the bound HIF-ODDD was stored at 41C for further use. Subsequent ubiquitin immunoblotting was performed using anti-ubiquitin polyclonal antisera (Sigma Chemicals).
p300 CH1 binding
The bacterial glutathione fusion vector encoding the human p300 CH1 domain was a gift from Dr Daniel J Peet and David Lando (School of Molecular Life Sciences, Adelaide University) and has been described previously (Lando et al., 2002a) . To bind full-length HIF-1a to recombinant glutathione-sepharose-conjugated p300 CH1, RCC4 cells or RCC4 cells expressing various recombinant forms of VHL were harvested in WCE buffer and approximately 500 mg of protein extract was incubated with p300 CH1 at 41C for 1 h in a buffer containing 20 mM Tris pH 7.5, 20 mM ZnCl2, 0.05% Triton X-100 and 100 mM KCl. The p300 CH1 column was washed 3 Â with 20 volumes of incubation buffer and SDS-PAGE sample buffer added to the samples prior to electrophoresis and immunoblotting with anti-HIF-1a antisera.
Reporter assays
The HIF response element (HRE)-luciferase reporter construct used in this study has been described previously (Ema et al., 1997) . Reporter assays were carried out according to the instructions provided in the Promega dual-luciferase reporter assay manual provided with the kit (Promega) using a renilla-luciferase reporter construct (pTKRL, Promega) as the internal control. At 12 h following transfection of the relevant plasmids into 24-well plates (25 ng of each reporter construct, 50 ng of VHL cDNA and 50 ng of HIF-1a/EF-IRES-puromycin cDNA), cells were exposed to 21, 2 or o1% oxygen for a further 16 h and activities were expressed as a ratio of HRE firefly-luciferase activity/renilla luciferase. Assays for each C-terminal deletion of VHL were performed in triplicate.
Results and discussion
In the first part of the study, we generated recombinant RCC cell lines stably expressing either wild-type VHL or various C-terminal truncations described schematically in Figure 1a .
In Figure 1b , the site of these deletions is shown on helix 4 (H4) of the VHL structure derived previously (Stebbins et al., 1999; Min et al., 2002; Hon et al., 2002) , which is in turn displayed interacting with b-strands S2, S3 and S5 of the VHL b-sandwich (summarized topologically, Figure 1b) . In Figure 1c , VHL C-terminal deletions were first tested in their ability to downregulate HIF-1a. In RCC4 cells, HIF-1a is expressed at relatively high levels, consistent with the absence of functional VHL. When the recombinant forms of VHL described in Figure 1a were stably transfected into RCC4 cells, all C-terminal deletions downregulated HIF-1a to almost undetectable levels during normoxia, suggesting that the C-terminus of VHL is not an absolute prerequisite for the binding and ubiquitination of HIF-1a. How such changes might affect HIF-1a downregulation in a whole organism is not yet clear, although it is worthwhile noting that deletions and mutations in the C-terminal region investigated in this study lead to VHL disease (Crossey et al., 1994; Whaley et al., 1994; Zbar et al., 1996) , and thus might be assumed to do so via mechanisms independent of HIF-1a overexpression.
Given these initial findings, it appeared that the C-terminal domain of VHL had little effect on its function as an E3 ligase, even though mutations in the region are associated with VHL disease. We therefore tested whether changes in the C-terminal region of VHL caused an alteration in its ability to ubiquitinate HIF-1a over time. In Figure 2 , the rate of degradation and extent of ubiquitination of HIF-1a was determined in RCC4 cells stably expressing different VHL C-terminal deletions. Following the removal of DPP, HIF-1a is degraded at different rates depending on the type of C-terminal deletion (Figure 2a and b) . Relative to the full-length VHL/E3 ligase, all deletions exhibited deficiencies in the removal of HIF-1a (Figure 2b ), which largely correlated with the stepwise removal of the Cterminal a-helix. Interestingly, the extent of ubiquitination of HIF-1a differed quite markedly depending on the deletion, with forms VHL-205 and VHL-201 exhibiting substantially more ubiquitinated HIF-1a when compared to . In comparison with VHL-205 and VHL-201, full-length VHL exhibited less ubiquitinated HIF-1a following DPP withdrawal, which most likely reflects an overall increase in the rate of ubiquitination and degradation of HIF-1a with an intact VHL C-terminal a-helix. In terms of VHL E3 ligase function towards HIF-1a, we suggest that C-terminal deletions can be grouped in terms of the severity of their effect, with VHL-205 and VHL 201 exhibiting comparably more ubiquitin-conjugating activity than those containing the two deletions, . It is therefore proposed that the packing created by hydrophobic interactions between the Cterminal domain (H4) of VHL and the b-sheet formed by S2, S3 and S5 of the VHL b-sandwich are essential for full VHL E3 ligase activity.
To determine the molecular basis of the changes in VHL-mediated ubiquitination of HIF-1a observed in Figure 2 , we tested the ability of different VHL Cterminal deletions to bind to HIF-1a (Figure 3) . In Figure 3a , VHL stably expressed in RCC4 cells was incubated with proteasome inhibitor and VHL immunoprecipitated at different salt concentrations along with the bound HIF-1a. At salt concentrations of 0.5 M, full-length VHL, VHL-205 and VHL-201 pulled down comparable amounts of HIF-1a relative to input; however, when salt concentrations were raised to 1.0 M, approximately half of the HIF-1a captured at 0.5 M was lost in VHL-205-and VHL-201-expressing cells. By contrast, the efficiency with which the fulllength VHL captured HIF-1a at 1.0 M KCl was unaltered. When full-length VHL/HIF-1a pull-downs were compared to those obtained with , it was apparent that even at 0.5 M KCl the efficacy with which these C-terminal truncations captured HIF-1a was lower. The data from several of these experiments are summarized in Figure 3b and c, and highlight the substantial loss in VHL binding to HIF-1a obtained when deleting a further four amino acids from position 201. In general, these data were in agreement with the changes in the ubiquitination of HIF-1a observed in Figure 2 , and indicates that the molecular basis for impaired ubiquitination with VHL C-terminal deletions is a result of impaired substrate binding by the Figure 1 Generation of recombinant C-terminal truncations of VHL and their effects on HIF-1a downregulation during normoxia. In (a), multiple C-terminal deletions, point mutations and C-terminal fusions of HA-tagged VHL (designated as VHL for simplicity) were generated using primers as described in Experimental procedures. The various modifications are shown schematically. In (b(I)), the Cterminal a-helical domain of VHL (aa 195-208, H4 ) is shown relative to the two other major functional domains of the protein; the bdomain (substrate binding, aa 64-154, S1-S7) and a largely a-helical domain including the elongin B/C-binding box (aa 157-189). The C-terminal VHL deletions investigated in this study are shown in the figure and extend from the naturally occurring RCC causing mutation, VHL-Gln195Term (VHL-194) to position 205. The remaining C-terminal 5 aa of VHL have not been crystallized. A topological diagram of the VHL structure is also shown with b-strands and a-helices marked as described previously (3). In (b(II)), the C-terminal helix is proposed to form part of the VHL b-domain by virtue of hydrophobic interactions with part of a substrate-binding b-sheet (S2, S3 and S5) comprising the larger VHL b-sandwich (aa 64-154, (3)). In (c), RCC4 cells were stably transfected with either full-length VHL or the C-terminal truncations of VHL described in Figure 1(a) . Cell lines expressing the various recombinant forms of VHL were then lysed using whole-cell extract (WCE) buffer, protein content determined and 100 mg of sample loaded, and run on 6% (HIF-1a) or 10% (VHL, 12CA5) SDS-PAGE gels. Gels were transferred to nitrocellulose and probed with monoclonal antibodies to either HIF-1a or VHL. HIF-1a migrated at an approximate M r of 130 kDa throughout these experiments, HA-tagged VHL and variants thereof at an approximate Mr of 28-35 kDa VHL E3 ligase. Thus, in principle, the rate at which ubiquitin can be transferred to the target protein is attenuated.
HIF-1a has been demonstrated to contain two VHLbinding sites within its oxygen-dependent degradation domain (HIF-ODDD; Epstein et al., 2001; Masson et al., 2001) . It is unclear as to how changes in VHL structure might differentially affect the ubiquitination and degradation of these two separate domains, particularly from the perspective of disease-causing mutations. We tested this possibility within the context of the present study by assessing the ubiquitination and degradation of both Nand C-terminal HIF-ODDD domains with either fulllength VHL or VHL-194 ( Figure 4) . As shown, when expressed in 786-0/VHL or 768-0/VHL-194 cells, the Nterminal HIF-ODDD was induced by DPP or proteasome inhibitor to a similar extent (compare lanes 2, 3-5, 6). However, there were no detectable ubiquitin conjugates isolated by purification of the N-terminal HIF-ODDD under any conditions (Figure 4, lanes 1-6) . By contrast, the coexpression of the C-terminal HIF-ODDD in 786-0/VHL and 786-0/VHL-194 cells revealed a difference in its ubiquitination relative to the N-terminal HIF-ODDD. In both 786-0/VHL and 786-0/VHL-194 cells, the C-terminal HIF-ODDD is induced by DPP and MG132, but in 786-0/VHL cells there was evidence of substantially higher levels of ubiquitinated HIF-ODDD (Figure 4, lane 9) than the Cterminal mutant (lane 12). We conclude, therefore, that the rate of ubiquitination of the HIF-1a N-terminal ODDD by VHL is lower than that of the C-terminal ODDD. Furthermore, the C-terminal a-helix of VHL is required for efficient ubiquitination of the C-terminal HIF-ODDD, but has little detectable influence on Nterminal HIF-ODDD regulation. Such data likely reflect different requirements in the binding and ubiquitination of the two discrete domains, a result that is perhaps unsurprising since apart from the 'LAP' motif (Epstein et al., 2001; Masson et al., 2001) , the domains share little homology.
To attempt to place the findings from Figures 2-4 within a biological context, we exposed RCC4 cells expressing varying C-terminal deletions of VHL to graded hypoxia (Figure 5a ). In general, cells exposed to 5% oxygen showed only a slight induction of HIF-1a above normoxic levels, consistent with a previous study detailing the inducibility of HIF-1a in HeLa cells (Jiang et al., 1996a) . However, when cells were exposed to 2% oxygen differences were apparent, most noticeably between RCC4/VHL cells and RCC cells stably expressing VHL truncations of greater than 12 aa . Maximal HIF-1a induction was observed at 2% oxygen in these C-terminal truncated lines as opposed to o1% hypoxia in RCC4 cells expressing full-length VHL. The data suggest that Cterminal VHL truncations cause a shift in the oxygen dependency of HIF-1a induction at low molecular oxygen. To determine whether these changes affected the transcriptional activity of HIF-1a, we assessed HRE-mediated GLUT1 expression following graded hypoxia ( Figure 5b ). As shown, even small C-terminal deletions (8 or 12 aa) result in increased GLUT1 expression at partial hypoxia when compared to RCC4 or 786-0 cells expressing full-length VHL. These findings suggest that even at moderate levels of oxygen deprivation some of the HIF-1a expressed in cell lines containing C-terminal VHL truncations escapes proteolysis and is transcriptionally active.
To test formally the transcriptional potential of HIF1a derived from RCC4 cells expressing full-length VHL or C-terminal truncations, we induced HIF-1a via treatment with 2% oxygen and determined the amount bound to the CH1 domain of p300 (Figure 6 ). First, under these binding conditions, HIF-1a derived from a VHL line (RCC4) binds constitutively to the p300 CH1 domain (Figure 6a ), consistent with the high basal HIFmediated gene expression observed in this line (Figure 5b) . At 2% oxygen, we were able to detect an interaction of HIF-1a with p300 CH1 using HIF-1a derived from RCC4/VHL-194 cells but not from RCC4/ VHL-213 cells (Figure 6b ). To date, we do not know whether coactivators such as p300 compete with VHL for HIF-1a, or for that matter, other factors such as Figure 1 . Results are from a single representative experiment and show the position of HIF-1a and ubiquitin-HIF-1a conjugates, generated upon the removal of DPP. Note that the levels of ubiquitinated HIF-1a differ markedly depending on the VHL C-terminal deletion. SDS-PAGE cell extracts from this experiment were also probed for the ER chaperone, BiP, to confirm equal sample loading. In (b), several of the experiments described in (a) were performed on each cell line and the levels of HIF-1a calculated from immunoblots by laser densitometry following DPP treatment and removal. Each bar on the y-axis represents the mean7s.d. of at least three separate determinations. Results for each cell line utilized 5 h DPP treatment as a measure of maximal HIF-1a induction, normalized to 100% arbitrary densitometric units (ADUs). The remaining HIF-1a following 30 min DPP withdrawal is calculated relative to this value
The VHL C-terminus and VHL disease MD Lewis and BJ Roberts Figure 3 The C-terminus of VHL is required for high-affinity binding to HIF-1a. In (a), HIF-1a was purified via its interaction with VHL under conditions of medium (0.5 M) or high (1.0 M) salt. RCC4 cells stably transfected with VHL-213, were incubated with MG132 (20 mM) for 4 h and cells harvested using WCE buffer as described in Figure 1 . VHL/HIF-1a complexes were then precipitated using anti-HA IgG (12CA5) as described in Experimental procedures in the presence of 0.5 or 1.0 M KCl. SDS-PAGE sample buffer was added to the immunoprecipitates, which were then electrophoresed and immunoblotted as in Figure 1 . In each case, the input HIF-1a from each WCE is loaded in the first three columns and compared to the quantity captured by VHL. In (b), HIF-1a binding to VHL-213 and VHL-205 was directly compared following MG132-induced stabilization of HIF-1a and immunoprecipitation of VHL in buffers containing 0.5, 1.0 and 1.5 M KCl. Experiments were performed in triplicate and the level of HIF-1a precipitated with VHL determined by laser densitometry. Results represent mean values7s.d. normalized to the percentage of HIF-1a recovered at 0.5 M KCl. In (c), the binding of HIF-1a to VHL under varying salt conditions is summarized in tabular format. Results represent observations from several experiments with binding scored accordingly Figure 4 The C-terminal a-helical domain of VHL is required for efficient ubiquitination of the C-terminal HIF-ODDD but not the N-terminal ODDD. VHL or VHL-194 was stably transfected into 786-0 cells followed by either the 6 Â HIS/6 Â myc-tagged HIF-1a Nterminal (aa 343-509) or C-terminal (aa 416-580) ODDD regions (see Experimental procedures for further details of these constructs and cell lines). Cells were then treated with either DPP (100 mM) or MG132 (10 mM) for 4 h. Cells were harvested, WCEs prepared, equal protein samples loaded onto 10% SDS-PAGE gels, transferred and immunoblotted with 9E-10 (anti-myc) antibody. The position of the recombinant HIF-ODDD regions is shown on the gel, with nonspecific bands denoted as 'NS' on the figure. The samples were then rerun on 10% SDS-PAGE gels and probed with 12CA5 IgG to detect comparative VHL expression. For ubiquitin staining, cells treated identically to those shown for anti-myc staining were harvested, extracts prepared and equal amounts of sample protein purified by nickel chromatography as described in Experimental procedures. The purified material was run on 10% SDS-PAGE gels to determine that HIF-ODDD recovery was approximately equal (as determined by anti-myc immunoblotting), then run on 6% SDS-PAGE gels, transferred to nitrocellulose and probed for ubiquitin conjugates using polyclonal anti-ubiquitin IgG FIH-1 (Mahon et al., 2001; Hewitson et al., 2002; Lando et al., 2002b) , corepressors (Mahon et al., 2001) or ARNT (Jiang et al., 1996b) . If so, altering the affinity of VHL for HIF-1a may, in addition to factors such as proline hydroxylation, affect the ability of other proteins to interact with and stabilize HIF-1a. In Figure 6c , we tested the role of the C-terminal region of VHL in repressing HIF-mediated gene expression using a luciferase gene under the control of several HREs. Each C-terminal deletion resulted in a higher basal HREmediated gene expression under normoxia, and also under hypoxic conditions. At 2% oxygen, reporter activity from approached that observed at o1% oxygen, suggesting higher sensitivity to hypoxic gene regulation. Overall, the data presented in Figure 6c support the concept that C-terminal truncations, if found in whole organisms, would likely lead to increased transcription of both HIF-and HLF-responsive genes, and might thereby predispose them to the vascular tumours observed in the VHL-195-Gln-Term genotype (Crossey et al., 1994) . Figure 5 Effects of VHL C-terminal truncations on the induction of HIF-1a and associated HRE-mediated GLUT1 expression during graded hypoxia. In (a(I)), RCC4 cells alone or stably transfected with full-length VHL or C-terminal truncations were exposed to different oxygen tensions for 4 h as described in Experimental procedures. Cells were harvested, protein determined and HIF-1a levels determined by immunoblotting as per Figure 1 . Data shown are representative of experiments repeated on at least three separate occasions. In (a(II)), different hypoxic levels and their effects on HIF-1a induction in RCC4/VHL-205 and RCC4/VHL-213 cells are directly compared on the same gel via immunoblotting of HIF-1a. As a control, VHL levels from the same extracts are shown in a 12CA5 immunoblot directly below. In (b(I)), RCC cells alone or stably transfected with either full-length VHL, were exposed to either 21, 5 or 2% oxygen. Cells were harvested following 20 h exposure and protein extracts obtained as per Figure 1 using WCE. Equal quantities of protein extract were then added to a saturated urea solution at a 3 : 1 v/v ratio, mixed and then added to SDS-PAGE sample buffer. Unboiled samples were then loaded onto 10% SDS-PAGE gels, subjected to electrophoresis, transferred to nitrocellulose and immunoblotted with a monoclonal anti-GLUT1 IgG. As a control, the same extracts were also probed for VHL using 12CA5 IgG. In (b(II)), 786-0 cells stably transfected with VHL-213, VHL-205, VHL-201 or VHL-194 were exposed to 5% O 2 for 24 h, cells harvested, WCE extracts prepared and GLUT1 protein expression on equally loaded protein samples determined as in (b). As per (b(I)), the same cell extracts were also probed for VHL to ensure comparable VHL expression and loading
The structural significance of the C-terminus of VHL and its relationship to function is unknown, other than the mutations in it that give rise to VHL disease. A recent study crystallizing VHL with the minimal 20 aa C-terminal ODDD of HIF-1a showed no special requirement for an intact C-terminus (Hon et al., 2002; Min et al., 2002) ; however, the second N-terminal ODDD of HIF-1a (Epstein et al., 2001; Masson et al., 2001) has not thus far been investigated within this context, nor the possibility of further contact or stabilizing points of the C-terminus with an extended ODDD architecture. Whatever the case, it is clear that an intact VHL C-terminal a-helical domain is required for stable, high-affinity binding to the ubiquitination target, probably via secondary folding effects on the adjacent VHL b-sheet (Figure 1b and (Stebbins et al., 1999) ). Cooperatively, this structure enables efficient HIF-1a ubiquitination via proline 564 and is less significant in regulation via proline 402 (Figure 4) .
The data presented in this study highlight the need to examine the VHL/E3 ligase in detail, since some parameters used to assess VHL function show little or no change until properties of the VHL E3 ligase are more thoroughly investigated. Clearly, there are also differences in VHL function that only become evident when factors such as binding affinity are altered, the example in this study being hypoxic stress. In summary, we have defined a role for the C-terminal a-helical domain of VHL in its function as a ubiquitin ligase, and suggest that this domain, in addition its role in HIF-1a ubiquitination, may be necessary for other antitumour properties associated with VHL.
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Figure 6 C-terminal truncations in VHL allow HIF-1a to interact with the p300 CH1 domain during partial hypoxia. In (a), RCC4 cells alone or treated with DPP (100 mM, 3 h) were harvested in WCE and incubated with bacterially expressed p300 CH1 domain as described in Experimental procedures. Note that HIF-1a prepared from RCC4 cells alone binds efficiently to the p300 CH1 domain in the presence or absence or DPP. In (b), the p300 CH1 domain-binding assay was repeated using RCC4/VHL or RCC4/VHL-194 cells following exposure to 2% oxygen for 4 h. In the case of hypoxic binding, PBS, WCE and binding buffers were equilibrated at 2% oxygen for 16 h prior to harvesting of cells. Results represent data obtained from two to three separate experiments. In (c), a dual-luciferase reporter assay was performed in triplicate using the various cDNAs encoding VHL C-terminal truncations. In each case, the cDNA encoding VHL was cotransfected with a cDNA encoding human HIF-1a using the same vector backbone. Transfections and hypoxic treatments were conducted as described in Experimental procedures. Results are represented on the y-axis as the mean7s.d. of triplicate determinations calculated as relative luciferase units (RLUs) 
